Monopar Therapeutics (MNPR) EBIT: 2016-2019
Historic EBIT for Monopar Therapeutics (MNPR) over the last 4 years, with Dec 2019 value amounting to -$4.3 million.
- Monopar Therapeutics' EBIT fell 32.23% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.3 million, marking a year-over-year decrease of 36.88%. This contributed to the annual value of -$4.3 million for FY2019, which is 29.80% down from last year.
- Latest data reveals that Monopar Therapeutics reported EBIT of -$4.3 million as of FY2019, which was down 29.80% from -$3.3 million recorded in FY2018.
- In the past 5 years, Monopar Therapeutics' EBIT registered a high of -$1.2 million during FY2016, and its lowest value of -$16.6 million during FY2017.
- Over the past 3 years, Monopar Therapeutics' median EBIT value was -$4.3 million (recorded in 2019), while the average stood at -$8.1 million.
- Per our database at Business Quant, Monopar Therapeutics' EBIT slumped by 1,291.91% in 2017 and then surged by 79.94% in 2018.
- Yearly analysis of 4 years shows Monopar Therapeutics' EBIT stood at -$1.2 million in 2016, then crashed by 1,291.91% to -$16.6 million in 2017, then surged by 79.94% to -$3.3 million in 2018, then declined by 29.80% to -$4.3 million in 2019.